Thyroid Diseases: Clinical Trials

36 trials for Thyroid Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 unknown. 36 Phase 2, 7 Phase 3, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 236Unknown 36
Phase 37Unknown 7
Phase 15Unknown 5

Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
20 mg Famitinib & 1200 mg Adebrelimab - Thyroid Cancer
Phase 2UnknownRuijin Hospital672023-12-012023-11-28
Effect of Vitamin C Supplementation in Patients With Primary Hypothyroidism
Vitamin C, Oral Rehydration Salt Formulations - Hypothyroidism, Primary Hypothyroidism
Phase 2UnknownDr Adnan Agha402023-11-012024-01-11
Graves' Disease Remission Study: MycoMeth Combo
Mycophenolate Mofetil, Oral, 250 Mg, methimazole, oral, 10mg - Graves' Disease
Phase 2 / Phase 3UnknownThe First Affiliated Hospital of Xiamen University2052023-10-162024-02-28
Patient-Customized Bioprinting Technology for Practical Regeneration of the Respiratory Tract (Trachea)
Three-dimensional patient-specific bioprinting trachea implantation - Thyroid Cancer
Phase 1 / Phase 2UnknownJa Seong Bae, MD, phD12023-07-172023-09-25
A Study of DB-1202 Monotherapy in Advanced Solid Tumors
DB-1202 - Advanced Solid Tumor
Phase 1 / Phase 2UnknownDualityBio Inc.1502023-06-282023-03-31
Sirolimus for Graves' Orbitopathy (GO)
Sirolimus - Graves Ophthalmopathy
Phase 2UnknownUniversity of Pisa542023-06-012023-03-15
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
Tislelizumab, Anlotinib, Radiotherapy - Thyroid Cancer
Phase 2UnknownWest China Hospital202022-12-302022-12-21
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
Dabrafenib 75 MG, Trametinib 2 MG - Thyroid Cancer
Phase 2UnknownOlivia Newton-John Cancer Research Institute802022-07-142023-10-31
Bupivacaine Versus Lidocaine Infiltration for Postoperative Pain in Thyroid Surgery
Bupivacaine 0.5% with 1:200 000 epinephrine, Lidocaine 2% with 1:100 000 epinephrine - Postoperative Pain, Thyroid Diseases
Phase 2UnknownSt. Joseph's Healthcare Hamilton2102022-06-012023-11-28
A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease
HBM9161 680 mg qw by q2w from week 13, Placebo, HBM9161 680 mg qw by q2w from week 7 - Thyroid Ophthalmopathy
Phase 2 / Phase 3UnknownHarbour BioMed (Guangzhou) Co. Ltd.362021-09-222022-02-23
Anlotinib or Penpulimab in Combination With RAI for DTC
Anlotinib hydrochloride, Sodium Iodide I 131, Penpulimab - Thyroid Cancer
Phase 2UnknownPeking Union Medical College Hospital422021-09-152022-01-28
Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry
Radioiodine optimized therapy - Metastatic Differentiated Thyroid Cancer
Phase 2UnknownCarlo Chiesa502021-05-122022-03-29
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
dabrafenib and trametinib - Thyroid Cancer
Phase 2UnknownNational University Hospital, Singapore52020-12-302021-03-05
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
Camrelizumab and Apatinib, surgery, core needle biopsy - Thyroid Cancer
Phase 2UnknownFudan University312020-12-012020-11-03
Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
Surufatinib, Toripalimab - Thyroid Cancer
Phase 2UnknownFudan University102020-10-012020-08-24
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Anlotinib, surgery, core needle biopsy - Thyroid Cancer
Phase 2UnknownFudan University132019-06-012021-04-01
Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers
Apatinib - Thyroid, Metastasis
Phase 2UnknownNanjing First Hospital, Nanjing Medical University102019-04-102019-11-27
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST
Phase 1 / Phase 2UnknownInstitut BergoniƩ7472018-05-042023-03-03
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition
Trametinib 2 MG [Mekinist], Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar] - Metastatic Thyroid Cancer
Phase 2UnknownUniversity Hospital, Essen702018-02-052023-06-22
Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer
Apatinib, Intensity modulated radiation therapy - Thyroid Cancer
Phase 2UnknownXiayun He, MD202017-07-012017-10-03

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Thyroid Neoplasms (21)  ·  Graves Ophthalmopathy (5)  ·  Graves Disease (4)  ·  Adenocarcinoma, Follicular (3)  ·  Stomach Neoplasms (3)  ·  Thyroid Cancer, Papillary (3)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Renal Cell (2)  ·  Colonic Neoplasms (2)  ·  Head and Neck Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)  ·  Thyroid Carcinoma, Anaplastic (2)

Broader conditions

Endocrine System Diseases (35)  ·  Endocrine Gland Neoplasms (22)  ·  Neoplasms (22)  ·  Neoplasms by Site (22)  ·  Head and Neck Neoplasms (20)  ·  Immune System Diseases (9)  ·  Autoimmune Diseases (8)  ·  Exophthalmos (8)  ·  Goiter (8)  ·  Orbital Diseases (8)  ·  Eye Diseases (7)  ·  Hyperthyroidism (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Genetic Diseases, Inborn (6)

Interventions

apatinib (4)  ·  dabrafenib (3)  ·  trametinib (3)  ·  Biopsy, Large-Core Needle (2)  ·  Bupivacaine (2)  ·  Iodine-131 (2)  ·  Radiotherapy (2)  ·  Surgical Procedures, Operative (2)  ·  anlotinib (2)  ·  Ascorbic Acid (1)  ·  Botulinum Toxins, Type A (1)  ·  Chlortetracycline (1)  ·  Clinical Trials, Phase II as Topic (1)  ·  Doxycycline (1)  ·  Everolimus (1)

Sponsors

Fudan University (3)  ·  National Cancer Center, Korea (2)  ·  Sun Yat-sen University (2)  ·  Carlo Chiesa (1)  ·  Chinese Academy of Medical Sciences (1)  ·  Dr Adnan Agha (1)  ·  DualityBio Inc. (1)  ·  Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1)  ·  Harbour BioMed (Guangzhou) Co. Ltd. (1)  ·  Hospices Civils de Lyon (1)  ·  Institut BergoniĆ© (1)  ·  Ja Seong Bae, MD, phD (1)  ·  Leiden University Medical Center (1)  ·  Nanjing First Hospital, Nanjing Medical University (1)  ·  National University Hospital, Singapore (1)

Countries

China (13)  ·  South Korea (4)  ·  Italy (3)  ·  France (2)  ·  Germany (2)  ·  United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Iran (1)  ·  Netherlands (1)  ·  Singapore (1)  ·  Switzerland (1)  ·  United Arab Emirates (1)

Top investigators

Dan Liang, MD (2)  ·  Adnan Agha (1)  ·  Alan B Scott, MD (1)  ·  Andrew M Scott, MD, FRACP (1)  ·  Babak Babsharif, MD (1)  ·  Carlo Chiesa, PhD (1)  ·  Electron Kebebew, MD (1)  ·  Ellen Kapiteijn, MD, PhD (1)  ·  Eun Kyung Lee, M.D.,Ph.D. (1)  ·  Fangsen Xiao, MD (1)  ·  Feng Wang, PhD MD (1)  ·  Furio Pacini, MD (1)  ·  Han Zhang, MD FRCSC (1)  ·  Huifang Zhou (1)

Results publications

PMID 18299459, PMID 20126486, PMID 22479375, PMID 26041482, PMID 26163763, PMID 26670972, PMID 27169792, PMID 27272078, PMID 27521067, PMID 27797318, PMID 29396246, PMID 30105951, PMID 30261427, PMID 30912336, PMID 32055040, PMID 32616746, PMID 32929476, PMID 34598995, PMID 34610756, PMID 34965951, PMID 34998048, PMID 35223896, PMID 35767182, PMID 35959915, PMID 36173609, PMID 36346684, PMID 40204996, PMID 40579407, PMID 41210509

NIH funding

2016 (2)